Consecutive court rulings on mifepristone have thrust access to the abortion pill back into the spotlight just weeks before the midterm elections. A federal appeals court limited mailed prescriptions, and the Supreme Court temporarily restored broader access while it reviews the case. Both pro-choice and anti-abortion groups are mobilizing: rights advocates call for federal protections, while opponents push for faster FDA action and tighter restrictions. Polling shows most Americans oppose nationwide bans on the drug and favor legal abortion in many cases.
Abortion Pill Rulings Return To Spotlight As Midterms Near — Courts, Polls And Political Pressure Collide
FILE - Boxes of the drug mifepristone sit on a shelf at the West Alabama Women's Center in Tuscaloosa, Ala., March 16, 2022. (AP Photo/Allen G. Breed, File)(ASSOCIATED PRESS)
NEW YORK (AP) — Consecutive court decisions about access to the abortion pill mifepristone have pushed the issue back into the national spotlight as voters head into this year’s midterm elections, which will determine control of Congress for the second half of President Donald Trump’s term.
What Happened
On Friday, a federal appeals court restricted the mailing of mifepristone prescriptions, marking the most significant federal change to abortion policy since the Supreme Court allowed states to enforce abortion bans in 2022. On Monday, the Supreme Court temporarily restored broader access to the medication while it reviews the case, creating the prospect of a far-reaching final decision that could affect patients, providers and telehealth services nationwide.
Political Stakes
Both sides are already using the rulings to try to influence turnout in the midterms. Abortion rights groups are ramping up outreach and messaging — including targeted contact with voters who backed Trump in recent state races but support abortion access — arguing that only federal legislation can stabilize access across all 50 states. Anti-abortion groups, meanwhile, are pressing the Food and Drug Administration for a faster safety review of mifepristone and calling on the administration to tighten rules or restrict telehealth prescribing.
This is a five-alarm crisis for the pro-life movement and for the GOP, warned Marjorie Dannenfelser, president of SBA Pro-Life America, as conservative activists urged stronger action from the White House and the FDA.
Pressure On Regulators And Politicians
Anti-abortion organizations have urged FDA Commissioner Dr. Marty Makary to complete the mifepristone safety review quickly; some even called for his removal. Republicans are divided: some applaud steps the administration has taken, such as moves to withhold Planned Parenthood funding and investigations of state insurance mandates, while others criticize the president for not making abortion a central priority. Advocates on both sides say the court fight presents an opportunity to energize supporters.
Public Opinion And The Midterm Picture
Public views remain nuanced. A recent KFF poll found roughly two-thirds of Americans oppose a nationwide ban on mifepristone, and AP-NORC polling shows about two-thirds of U.S. adults say abortion should be legal in all or most cases. While the issue drove record turnout in some 2022 state votes that benefited Democrats, some Democratic strategists believe the immediate urgency had faded — until the recent rulings reminded voters that access via mail and telehealth is not guaranteed.
Why It Matters
The legal fight over mifepristone will likely continue to move through courts and federal review, but its political reverberations are immediate. The rulings and ensuing regulatory debate could reshape campaign messaging, influence turnout among key constituencies, and prompt renewed calls for federal legislation to protect or restrict medication abortion across states.
Associated Press writer Linley Sanders in Washington contributed to this report.
Help us improve.
